Multiple Myeloma
Conditions
Keywords
Relapsed Refractory Multiple Myeloma
Brief summary
The primary objective is to compare the time to progression (TTP) of three daily doses of thalidomide (100, 200 and 400 mg) with high-dose dexamethasone in relapsed refractory multiple myeloma (MM) patients and to subsequently select the optimum thalidomide dose in terms of median TPP and toxicity.
Interventions
DRUGThalidomide
Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
DRUGDexamethasone
High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
Sponsors
Celgene
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients, aged ≥ 18 years at the time of signing the informed consent form * Patients who have been previously diagnosed with MM who have received between 1 & 3 prior lines of treatment for their disease, and who require therapy because of disease progression * Secretory MM with measurable levels of monoclonal protein in serum (\> 10 g/L of IgG M-protein or \> 5 g/L of IgA M-protein) or urine (≥ 200 mg/ 24hours); Patient with the following rare subclasses of the immunoglobulin: IgD, IgE, IgM can be included in the study if the level of monoclonal protein in serum is \> 5g/L or ≥ 200 mg/24hours in urine. As IgM immunoglobulin isotype can be related to Waldenstrom's macroglobulinemia, it is important to distinguish and not include in the study patients with Waldenstrom's macroglobulinemia. * ECOG performance status of 0, 1, or 2 * Life expectancy \>3months * Able to adhere to the study visit schedule & other protocol requirements * Women of child-bearing potential must agree to use 2 methods of contraception for at least 4weeks before starting the therapy, during the Treatment Period, & for 4 weeks after the last dose * Males must agree to use barrier contraception (latex condoms) when engaging in reproductive activity during the Treatment Period & for 4 weeks after the last dose * Written, informed consent
Exclusion criteria
* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the Informed Consent Form * Pregnant or lactating women. A serum β-hCG pregnancy test must be performed at the Screening visit for female patients of child-bearing potential. If the test is positive, the patient must be excluded from the study. Confirmation that the patient is not pregnant must be established by a negative serum or urinary pregnancy test with the result obtained 1day prior to the Baseline visit (or the day of the visit if results are available before drug delivery). A pregnancy test is not required for naturally post-menopausal women (who have not had menses at any time in the preceding 24 consecutive months) or surgically sterilized women (hysterectomy, bilateral ovariectomy, bilateral salpingectomy) * Non-secretory MM * Any of the following laboratory abnormalities: Absolute neutrophil count (ANC) \<500 cells/mm3 (0.5 x 109/L); Platelet count \<30,000/mm3 (30.0 x 109L) without transfusion support within 7 days before the test; Serum creatinine \>3.0mg/dL (265μmol/L); Serum aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) \>3.0 x upper limit of normal (ULN); Serum total bilirubin \>2.0mg/dL (34μmol/L) * Any condition, including the presence of laboratory abnormalities, which places the patient at unacceptable risk if s/he were to participate in the study, or which confounds the ability to interpret data from the study * Severe cardiac dysfunction (according to the New York Heart Association \[NYHA\] classification III-IV) * Severe bradycardia (\<50bpm) * Peripheral neuropathy ≥Grade 2 in severity (according to the NCI CTC Version 3.0) * Prior history of malignancy (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the patient has been free of disease for ≥5years * Patient received any chemotherapy, corticosteroids (\> 10 mg/day prednisone or equivalent as a continuous dose) within 4 weeks before randomization * Previously treated with thalidomide or thalidomide derivatives * Patients refractory to high-dose dexamethasone (defined as experiencing less than a PR to dexamethasone, or PD within 6months after discontinuing dexamethasone, or discontinued dexamethasone because of ≥Grade 3 dexamethasone-related toxicity. Previous high-dose dexamethasone therapy is defined as \>500mg dexamethasone or equivalent over a 10week period, whether administered alone or as part of the VAD regimen) * Contraindications for high-dose dexamethasone * Active or chronic gastrointestinal ulcers, active viral infections (herpes, varicella, HIV, hepatitis B, hepatitis C), glaucoma, uncontrolled hypertension, or diabetes mellitus, unless well controlled & under strict supervision during dexamethasone treatment * Patient enrolled in another clinical trial or who have participated in another trial with the last 4weeks before randomization
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The evaluation of Independent Review Committee-documented time to progression (TTP). | >160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms |
Secondary
| Measure | Time frame |
|---|---|
| Response duration | Every 4 weeks |
| Clinical benefit as measured by ECOG performance status, transfusion requirement and Grade ≥3 infections (assessed by the National Cancer Institute Common Toxicity Criteria) | Every 4 weeks |
| Progression-free survival (PFS) | Disease progression evaluated every 4 weeks |
| Overall survival (OS) | Evaluated after 150 deaths occurring in Dexamethasone and Thalidomide 400 mg arms |
| Composite of disease progression and death (recurrent time(s) from randomisation to disease progression and/or death) | Evaluated after 160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms |
| Response rate (CR + PR), according to the EBMT criteria | Every 4 weeks |
| Adverse events (AEs) | Every 4 weeks |
| Assessment of peripheral neuropathy | Screening, Week 24, Week 48 |
| Vital signs and physical examination | Every 4 weeks |
| Clinical laboratory tests | Every 4 weeks |
| Quality of life as determined by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) | Baseline/Week 8/ Week 16/Week 24/Week 32/Week 40/Week 48 |
Countries
Bulgaria, Croatia, Czechia, France, Germany, Hungary, India, Italy, Philippines, Poland, Portugal, Serbia, Slovakia, South Africa, United Kingdom
Outcome results
None listed